Quantitative analysis of the association between CRP rs2808630 and rs1417938 polymorphisms and cancer risk
- Authors:
- Jian‑Gong Wang
- Yang Zhang
- Tian‑Lin Xiao
View Affiliations
Affiliations: Department of Cancer Biotherapy, Cancer Institute, Tangshan People's Hospital, Tangshan, Hebei 063001, P.R. China, Department of Oncology, Xiangyang Central Hospital, Medical College, Hubei University of Arts and Science, Xiangyang, Hubei 441000, P.R. China
- Published online on: December 12, 2014 https://doi.org/10.3892/ol.2014.2796
-
Pages:
994-998
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Accumulating evidence indicates that polymorphisms in the CRP gene are important in the development of cancer. The current meta‑analysis was performed to investigate the association between CRP polymorphisms 3407 A>G (rs2808630) and 29 A>T (rs1417938), and the risk of developing cancer. A search of the relevant literature was conducted using the PubMed database to identify eligible studies published up until March 25, 2014. Five case‑control studies involving 888 cases and 3,167 controls for the 3407 A>G polymorphism, and six case‑control studies involving 3,110 cases and 5,951 controls for the 29 A>T polymorphism were included in the current meta‑analysis. The pooled odds ratios with 95% confidence intervals were calculated using the fixed‑ or random‑effects model. Meta‑analysis identified no association between the CRP 3407 A>G and 29 A>T polymorphisms, and overall cancer risk. Additional stratified analysis by cancer type did not reveal any significant associations in the genetic models investigated. The findings of the present study indicated that CRP 3407 A>G and 29 A>T polymorphisms are not associated with cancer risk.
View References
1
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
2
|
Volanakis JE: Human C-reactive protein:
expression, structure, and function. Mol Immunol. 38:189–197. 2001.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Kushner I, Jiang SL, Zhang D, Lozanski G
and Samols D: Do post-transcriptional mechanisms participate in
induction of C-reactive protein and serum amyloid A by IL-6 and
IL-1? Ann NY Acad Sci. 762:102–107. 1995. View Article : Google Scholar : PubMed/NCBI
|
4
|
Trichopoulos D, Psaltopoulou T, Orfanos P,
Trichopoulou A and Boffetta P: Plasma C-reactive protein and risk
of cancer: a prospective study from Greece. Cancer Epidemiol
Biomarkers Prev. 15:381–384. 2006. View Article : Google Scholar : PubMed/NCBI
|
5
|
Gao X, Zhang S, Qiao X, et al: Association
of cytotoxic T lymphocyte antigen-4 +49A/G polymorphism and cancer
risk: An updated meta-analysis. Cancer Biomark. 14:287–294.
2014.PubMed/NCBI
|
6
|
Pierce BL, Biggs ML, DeCambre M, et al:
C-reactive protein, interleukin-6, and prostate cancer risk in men
aged 65 years and older. Cancer Causes Control. 20:1193–1203. 2009.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Tsilidis KK, Helzlsouer KJ, Smith MW, et
al: Association of common polymorphisms in IL10, and in other genes
related to inflammatory response and obesity with colorectal
cancer. Cancer Causes Control. 20:1739–1751. 2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
Chaturvedi AK, Caporaso NE, Katki HA, et
al: C-reactive protein and risk of lung cancer. J Clin Oncol.
28:2719–2726. 2010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Xu M, Zhu M, Du Y, et al: Serum C-reactive
protein and risk of lung cancer: a case-control study. Med Oncol.
30:3192013. View Article : Google Scholar
|
10
|
Slattery ML, Curtin K, Poole EM, et al:
Genetic variation in C-reactive protein in relation to colon and
rectal cancer risk and survival. Int J Cancer. 128:2726–2734. 2011.
View Article : Google Scholar :
|